Top Markets
Coin of the day
Achilles Therapeutics plc Achilles Therapeutics plc

Achilles Therapeutics plc

ACHL
Rang in aandelen #24577
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused... Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Aandeelprijs
$1.48
Laatst gesynchroniseerd: 2025-03-24
Marktkapitalisatie
$59.05M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
GB
Handel Achilles Therapeutics plc (ACHL)

Categorie

Dividendrendementgeschiedenis voor Achilles Therapeutics plc (ACHL)
Het dividendrendement (TTM) van Achilles Therapeutics plc (aandelsymbool: ACHL) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Achilles Therapeutics plc (ACHL) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH